DOCSLIB.ORG

Butenafine Hydrochloride/Climbazole 529 to Be Reduced in Patients with Hepatic Impairment (See Profile Solution in Water Has a Ph of 8.0 to 9.0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Butenafine Hydrochloride/Climbazole 529 to Be Reduced in Patients with Hepatic Impairment (See Profile Solution in Water Has a Ph of 8.0 to 9.0 Butenafine Hydrochloride/Climbazole 529 to be reduced in patients with hepatic impairment (see Profile solution in water has a pH of 8.0 to 9.0. Protect from light. below). Chlormidazole hydrochloride is an imidazole antifungal used USP 31 (Ciclopirox Olamine). A white to slightly yellowish- topically as the hydrochloride in the treatment of fungal infec- white, crystalline powder. Slightly soluble in water; very soluble ◊ Reviews. tions of the skin. in alcohol and in dichloromethane; practically insoluble in cy- 1. Letscher-Bru V, Herbrecht R. Caspofungin: the first representa- For a discussion of the caution needed when using azole antifun- clohexane. pH of a 1% solution in water is between 8.0 and 9.0. tive of a new antifungal class. J Antimicrob Chemother 2003; 51: gals during pregnancy, see under Pregnancy in Precautions of Store in airtight containers at a temperature of 5° to 25°. Protect 513–21. Fluconazole, p.532. from light. 2. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445–57. Preparations Adverse Effects 3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: Proprietary Preparations (details are given in Part 3) Irritation and pruritus have been reported after topical applica- 1142–51. Pol.: Unifungicid. tion of ciclopirox. 4. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049–68. Multi-ingredient: Austria: Myco-Synalar; Pol.: Polfungicid; Switz.: Antimicrobial Action 5. Morris MI, Villmann M. Echinocandins in the management of Myco-Synalar†. Ciclopirox has a wide spectrum of antifungal activity. It inhibits invasive fungal infections, part 1. Am J Health-Syst Pharm 2006; most Candida, Epidermophyton, Microsporum, and Trichophy- 63: 1693–1703. ton spp. and is also active against Malassezia furfur. It has some 6. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health-Syst Pharm 2006; Chlorphenesin (BAN, pINN) antibacterial activity. 63: 1813–20. Chlorphénésine; Chlorphenesinum; Clorfenesina; Kloorifenesiini; Uses and Administration 7. Falagas ME, et al. Caspofungin for the treatment of fungal infec- Klorfenesin. 3-(4-Chlorophenoxy)propane-1,2-diol. Ciclopirox is an antifungal that is applied topically in the treat- tions: a systematic review of randomized controlled trials. Int J ment of fungal skin and nail infections, including cutaneous can- Antimicrob Agents 2007; 29: 136–43. Хлорфенезин 8. Hope WW, et al. The pharmacology and clinical use of caspofun- didiasis (p.518), dermatophytosis, pityriasis versicolor (see Skin C9H11ClO3 = 202.6. Infections, p.521), and seborrhoeic dermatitis (p.1584). It has gin. Expert Opin Drug Metab Toxicol 2007; 3: 263–74. CAS — 104-29-0. 9. Waters L, Nelson M. The use of caspofungin in HIV-infected in- also been used in the treatment of vaginal candidiasis. dividuals. Expert Opin Invest Drugs 2007; 16: 899–908. ATC — D01AE07. ATC Vet — QD01AE07. It is applied twice daily for skin infections, as a cream, gel, sus- Administration in children. Caspofungin is not licensed for pension, solution, or powder; both the base and the olamine salt use in paediatric patients, but has been prescribed.1 A retrospec- have been used, with products containing the equivalent of tive study2 of 25 immunocompromised children with a median OH 0.77% ciclopirox base. age of 9.8 years, given at least one dose of caspofungin, found A lacquer containing 8% ciclopirox base is applied once daily for that it appeared to be safe and well tolerated. Patients weighing O OH nail infections. less than 50 kg had a dose of 0.8 to 1.6 mg/kg daily, while those A shampoo containing 1% ciclopirox base is used twice weekly over 50 kg were given 50 to 75 mg daily. Another retrospective for the treatment of seborrhoeic dermatitis. 3 review of 64 immunocompromised children with a median age Cl of 11.5 years, reported a success rate of 67.7% with caspofungin ◊ References. at a median daily maintenance dose of 1.07 mg/kg, either as 1. Gupta AK, Skinner AR. Ciclopirox for the treatment of superfi- monotherapy or with another antifungal. A case series4 of 10 ne- Profile cial fungal infections: a review. Int J Dermatol 2003; 42 (suppl onates (9 preterm) with invasive candidiasis not responsive to Chlorphenesin has antifungal and antibacterial properties. It has 1): 3–9. been applied locally in mild uncomplicated dermatophyte and 2. Gupta AK, Nicol KA. Ciclopirox 1% shampoo for the treatment amphotericin B and/or fluconazole reported that Candida spp. of seborrheic dermatitis. Int J Dermatol 2006; 45: 66–9. were cleared from the blood in all patients in a mean of 4.3 days other cutaneous infections and in vaginal infections. after starting caspofungin therapy. Nine neonates were given an Chlorphenesin carbamate (p.1894) is used as a skeletal muscle Preparations initial dose of 1 mg/kg daily for the first 2 days followed by relaxant. USP 31: Ciclopirox Olamine Cream; Ciclopirox Olamine Topical Suspen- 2 mg/kg daily for 15 to 21 days; the other was given a lower Preparations sion. dose. Proprietary Preparations (details are given in Part 3) Proprietary Preparations (details are given in Part 3) 1. Lehrnbecher T, Groll AH. Experiences with the use of caspofun- Canad.: Mycil†; Ger.: Soorphenesin†; India: Dermicil†. Arg.: Dermaflor†; Loprox; Micopirox; Stieprox; Austral.: Stieprox; Aus- gin in paediatric patients. Mycoses 2008; 51 (suppl 1): 58–64. tria: Batrafen; Stieprox; Braz.: Fungirox†; Gino Loprox; Loprox; Micolami- Multi-ingredient: Austral.: ZSC; Austria: Aleot; Braz.: Oto Betnovate. 2. Franklin JA, et al. Retrospective study of the safety of caspofun- na; Micoliv†; Stiprox; Canad.: Loprox; Penlac; Stieprox; Chile: Batrafen; gin in immunocompromised pediatric patients. Pediatr Infect Fungopirox; Mikium†; Stiprox; Cz.: Batrafen; Dafnegin; Stieprox; Denm.: Dis J 2003; 22: 747–9. Mycofen; Stieprox; Fin.: Stieprox; Fr.: Mycosquam; Mycoster; Sebiprox; Sti- prox; Ger.: Batrafen; Ciclopoli; Inimur Myko; Nagel Batrafen; Sebiprox; Gr.: 3. Groll AH, et al. Treatment with caspofungin in immunocompro- Ciclopirox (BAN, USAN, rINN) Candimyc; Dafnegin†; Myclopir; Mycomycen; Neo-botacreme; Neo-myco- mised paediatric patients: a multicentre survey. J Antimicrob dermol; Rozolam; Stieprox; Hong Kong: Batrafen; Stieprox; Hung.: Batraf- Chemother 2006; 57: 527–35. Ciclopiroxum; Ciklopiroksas; Ciklopirox; Hoe-296b; Siklopiroksi. en; India: Olamin; Onylac; Indon.: Batrafen; Loprox; Irl.: Batrafen†; Oila- 4. Odio CM, et al. Caspofungin therapy of neonates with invasive 6-Cyclohexyl-1-hydroxy-4-methyl-2-pyridone. tum Scalp Treatment; Stieprox; Israel: Batrafen; Cicloderm; Ital.: Batrafen; candidiasis. Pediatr Infect Dis J 2004; 23: 1093–7. Biroxol†; Brumixol; Dafnegin; Miclast; Micomicen; Micoxolamina; Sebiprox; Циклопирокс Stiprox; Malaysia: Stieprox; Mex.: Loprox; Stiprox; Neth.: Loprox; Sebi- Patients with mild Administration in hepatic impairment. C H NO = 207.3. prox; Norw.: Stieprox; NZ: Batrafen; Stieprox; Philipp.: Stieprox; Pol.: hepatic impairment do not require dosage adjustment. In patients 12 17 2 CAS — 29342-05-0. Batrafen; Dafnegin; Hascofungin; Pirolam; Stieprox; Port.: Batrafen; My- with moderate hepatic impairment, a daily dose of caspofungin coster; Sebiprox; Rus.: Batrafen (Батрафен); Singapore: Stieprox; Spain: ATC — D01AE14; G01AX12. 35 mg should be used after the initial dose of 70 mg; appropriate Batrafen; Ciclochem; Fungowas; Rimafungol†; Sebiprox; Switz.: Batrafen; ATC Vet — QD01AE14; QG01AX12. Dafnegil Neo; Thai.: Cicloderm†; Loprox; Stieprox; Turk.: Canolen; Nibu- doses for patients with severe hepatic impairment have not been len; UK: Oilatum Scalp Treatment; USA: Loprox; Penlac; Venez.: Batrafen. established. Multi-ingredient: Arg.: Derm’s Shampoo; Stieproxal; Fr.: Novophane; Preparations Novophane S; Stiproxal; India: Flucort-C; Israel: Cicloderm-C; UK: Oila- OH tum Scalp Intensive. Proprietary Preparations (details are given in Part 3) Arg.: Cancidas; Austral.: Cancidas; Belg.: Cancidas; Braz.: Cancidas; Ca- N O nad.: Cancidas; Chile: Cancidas; Cz.: Cancidas; Denm.: Cancidas; Fin.: Cancidas; Fr.: Cancidas; Ger.: Cancidas; Gr.: Cancidas; Hong Kong: Can- Climbazole (BAN, rINN) cidas; Hung.: Cancidas; Irl.: Cancidas; Israel: Cancidas; Ital.: Cancidas; Malaysia: Cancidas; Neth.: Cancidas; Norw.: Cancidas; NZ: Cancidas; Bay-e-6975; Climbazol; Climbazolum; MEB-6401. 1-(p-Chlo- Philipp.: Cancidas; Pol.: Cancidas; Port.: Cancidas; Rus.: Cancidas rophenoxy)-1-imidazol-1-yl-3,3-dimethyl-2-butanone. (Кансидас); Singapore: Cancidas; Spain: Cancidas; Swed.: Cancidas; CH Switz.: Cancidas; Thai.: Cancidas; Turk.: Cancidas; UK: Cancidas; USA: 3 Климбазол Cancidas; Venez.: Cancidas. C15H17ClN2O2 = 292.8. Pharmacopoeias. In Eur. (see p.vii) and US. CAS — 38083-17-9. Ph. Eur. 6.2 (Ciclopirox). A white or yellowish-white, crystal- line powder. Slightly soluble in water; freely soluble in alcohol Chlormidazole Hydrochloride (BANM, rINNM) and in dichloromethane. Protect from light. O Chlormidazole, Chlorhydrate de; Chlormidazoli Hydrochlori- USP 31 (Ciclopirox). A white to slightly yellowish white, crys- CH3 dum; Clomidazole Hydrochloride; Hidrocloruro de clormidazol. talline powder. Slightly soluble in water; freely soluble in dehy- O 1-(4-Chlorobenzyl)-2-methylbenzimidazole hydrochloride. drated alcohol and in dichloromethane; soluble in ether. Store at a temperature of 15° to 30°. Protect from light. CH3 Хлормидазола Гидрохлорид N H3C Cl C15H13ClN2,HCl = 293.2. Ciclopirox Olamine (BANM,
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Fungi P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come
    P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come Fungi P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come Fungi Biology and Applications Second Edition Editor Kevin Kavanagh Department of Biology National University of Ireland Maynooth Maynooth County Kildare Ireland A John Wiley & Sons, Ltd., Publication P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come This edition first published 2011 © 2011 by John Wiley & Sons, Ltd. Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered Office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial Offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/ wiley-blackwell. The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • I|||||III US005567716A United States Patent 19 11 Patent Number: 5,567,716 Della Valle Et Al
    I|||||III US005567716A United States Patent 19 11 Patent Number: 5,567,716 Della Valle et al. (45) Date of Patent: Oct. 22, 1996 54 TRANS AND CISTRAUMATIC ACID SALTS Chemical Abstracts, vol. 83, No. 3, Abstract No. 29, 1165, p. HAVING CICATRIZANT ACTIVITY 40, Jul 21, 1975. ASSOCIATED TO BACTERIOSTATIC, Nakayama et al, Bull Chem. Soc. Jpn. vol. 64, pp. 358-365 ANTIVIRAL, ANTIBIOTIC OR ANTIFUNGAL (1991). ACTIVITY Breslow et al., J. Am. Chem. Soc., vol. 103 (10) pp. 2905-2907 (1981). 75) Inventors: Francesco Della Valle; Silvana Zimmerman etal, Plant Physiol. (1979) 63,536-541, "Iden Lorenzi, both of Padova, Gabriele tification of Traumatin, A Wound Hormone, as Marcolongo, Carrara San Giorgio, all 12-oxo-Trans-10 Dodecenoic Acid'. of Italy English et al., J. Biol. Chem. vol. 121, No. 2, (1937), 791-799, "The Wound Hormones of Plants: I. Traumatin, 73 Assignee: Lifegroup S.p.A., Rome, Italy the Active Principle of the Bean Test'. Goldemberg, J. Soc. Cosmet. Chem., 28, (Nov. 1977), 21 Appl. No.: 155,153 667-679, “Reduction of Topical Irritation”. Miyamoto et al, J. Soc. Cosmet, Chem. Japan, vol. 22, No. 22 Filed: Nov. 19, 1993 4, (1989), 254-262, "Effects of Cosmetics Containing Bio 30 Foreign Application Priority Data active Substances on Skin'. Rodriguez-Bigas et al, Plastic and Reconstructive Surgery, Nov. 23, 1992 IT Italy ................................. MI92A2674 vol. 81, No. 3 (Mar. 1988), 386-389, “Comparative Evalu (51) Int. Cl." ......................... A61K 31/195; A61K 31/20 ation of Aloe Vera in the Management of Burn Wounds in 52 U.S. Cl. .......................... 514/332; 534/676; 534/773; Guinea Pigs'.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,198,800 B1 K0 (45) Date of Patent: Apr
    US007 198800B1 (12) United States Patent (10) Patent No.: US 7,198,800 B1 K0 (45) Date of Patent: Apr. 3, 2007 (54) COMPOSITIONS AND METHODS (56) References Cited (75) Inventor: Thomas Sai Ying Ko. 4 Licence Road, U.S. PATENT DOCUMENTS Belgrave South, Victoria, 3160 (AU) 3,987,000 A * 10/1976 Gleichenhagen et al. ... 523/111 Y re. - - - 5,041.287 A * 8/1991 Driggers et al. .............. 424,81 (73) Assignee: Thomas Sai Ying Ko, Beijing (CN) 5,632,727 A * 5/1997 Tipton et al. ................. 602/47 5,708,023 A * 1/1998 Modak et al. .... ... 514,494 (*) Notice: Subject to any disclaimer, the term of this 5,725.491 A * 3/1998 Tipton et al. ................. 602/43 patent is extended or adjusted under 35 6,183,770 B1* 2/2001 Muchin et al. ............. 424/448 U.S.C. 154(b) by 781 days. * cited by examiner (21) Appl. No.: 09/717,088 Primary Examiner Sreeni Padmanabhan Assistant Examiner Gina Yu (22) Filed: Nov. 22, 2000 (74) Attorney, Agent, or Firm—Sughrue Mion, PLLC (30) Foreign Application Priority Data (57) ABSTRACT Nov. 23, 1999 (AU) ..................................... PQ4190 Non-aerosol spray-on skin patch compositions as described (51) Int. Cl. comprising at least one Substantially water insoluble film A6DF 3/00 (2006.01) forming agent, at least one film plasticizer agent, at least one AOIN 55/00 (2006.01) water soluble compound, and at least one organic solvent, (52) U.S. Cl. ...................... 424/443; 424/447; 424/448: the composition forming a flexible, porous and physiologi 424/449; 424/78.35: 525/363; 514/887: 514/494; cally compatible skin patch when sprayed on to skin and 602/43; 602/47 allowed to dry.
    [Show full text]
  • Determination of Antimycotic Substances, Derivatives
    Chem.Anal. (Warsaw), 41,19 (1996) Determination ofAntimycotic Substances, Derivatives ofImidazole', by ,Gas Chromatographic Method by,E. KlJblin andT. Kanjewska DepartmentofChemicalAnalysis, Institute ofDrugResearch and Control, 00-725 Warszawa, Poland Key words: bifonazole, chlormidazole, econazole nitrate, isoconazole nitrate, metroni­ dazole, miconazole, tioconazole, gas chromatography Simple method for gas-chromatographic identification of 7, among 9 used, antimycotic compounds, derivatives of imidazole has been elaborated. The conditions have been e~tablished for quantitative determination of selected compounds of this group present insubstlnces and such pharmaceuticals as ointments and creams. The column, packed with UCW-98 on Chromosorb WAW, and flame-ionisation ,detector were used. The, statistical data indicate satisfactory precision of the method, both in the determination ofimidazole derivatives in substances and in preparations. Opracowano prost<\,m'etod€( identyfikacji za pomoc<\, chromatografii gazowej 7, sposr6d 9 stosowanych, zwi<\,zk6w przeciwgrzybiczych, pochodnych imidazolu. Ustalono wa­ runki oznaczania ilosciowego wybral1ych zwi<\,zk6w z tej grupy w substancjach i pieparatach farmaceutycznych - masciach i kremach. Zastosowano kolumn€( wypetnio­ n<\, UCW-98 Ila Chromosorbie WAWoraz detektor 'ptomieniowo-jonizacyjny.' Dane statystyczne wykazuj<\, dostateczn<\,precyzj€( metody,zar6wno przy oznaczaniu zwi<\,z­ k6w - pochodnych imidazolu, w sUbstancjach, jak i w preparatach. Imidazole (1,3-diazole)derivatives are used
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Antifungals of the Azole Type
    RISK PROFILE Antifungals of the azole type This concerns azole type molecules used to eradicate or control fungi. They are used, or may potentially be used, for cosmetic purposes as defined in the European Commission database for cosmetic ingredients currently called CosIng. Date of reporting 24.11.201 4 This risk profile deviates in its format from other risk profiles in the series of pharmacological active substances as presented on the webpages of the Norwegian Food Safety Authority (NFSA). This is because the health risk arising because of use in cosmetics of these molecules mainly has to do with a potential worsening of the serious global problem of antimicrobial/antibiotic resistance/cross-resistance. The other risk profiles in this series concerns the toxicity of different cosmetics ingredients. The NSFA base this risk profile mainly on concerns expressed by the European Medicinal Agency (EMA) that on two occasions – in 2005 and 2011 - addressed the unfortunate use of azole type antifungals in cosmetics products. Also the NSFA observes that the same concern has been expressed by the Council of Europe in a publication as from 2008 concerning the use of Active ingredients in cosmetics. Over the years the Norwegian Medicinal Products Agency has strongly encouraged the NFSA forcefully to oppose any use of molecule in cosmetics that might potentially weaken the medicinal anti-fungus armamentarium against life threatening systemic fungal infections in people having a seriously compromised immune system. Over the years, also the European Commission has addressed this issue asking its scientific committee working in the field of cosmetic products - currently called the Scientific Committee on Consumer Safety (SCCS) - for advice.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]